Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | February 18, 2020 | February 19, 2020 |
| Immunovant, Inc.IMVT · Entity 3632 | Director · Chief Executive Officer | October 01, 2026 | October 05, 2026 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | President & Immunovant CEO | September 30, 2026 | October 02, 2026 |
| Sio Gene Therapies Inc.AXGT · Entity 130622 | Director | February 17, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 18, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Immunovant, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 257,075 |
Ending reported balance
After 2026-10-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 92,187 · Balance 346,467 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 2 · 2026-10-01 · Disposition to issuer · Disposed 85,886 · Balance 260,581 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 3 · 2026-10-02 · Sale · Disposed 3,506 · Balance 257,075 F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Capped Value Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2030-04-01 | Direct | 921,875 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 92,187 · Balance 921,875 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date.
F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026.
F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,599,154 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 200,000 · Balance 1,799,154 Row 2 · 2026-09-30 · Sale · Disposed 200,000 · Balance 1,599,154 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2032-04-19 | Direct | 3,644,834 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 200,000 · Balance 3,644,834 F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date February 17, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2023 Filed Sep 27, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 16,416 | $10.19 | $167,279.04 |
DisclosureSEC source: 0001140361-23-045331 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,397 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 106,430 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-043731 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,323,184 Underlying: Common Shares · 106,430 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 106,430 | $12.19 | $1,297,381.70 |
DisclosureSEC source: 0001140361-23-043731 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,813 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| September 08, 2023 Filed Sep 13, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 106,430 | $3.85 | $409,755.50 |
DisclosureSEC source: 0001140361-23-043731 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,926 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,429,614 Underlying: Common Shares · 5,926 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 5,926 | $11.85 | $70,223.10 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,813 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 5,926 | $3.85 | $22,815.10 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,275 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,435,540 Underlying: Common Shares · 73,275 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 73,275 | $11.92 | $873,438.00 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,813 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 73,275 | $3.85 | $282,108.75 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,763 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · derivative · entry 7 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,508,815 Underlying: Common Shares · 14,763 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 14,763 | $11.90 | $175,679.70 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,813 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 14,763 | $3.85 | $56,837.55 |
DisclosureSEC source: 0001140361-23-043005 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 626,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 16,105 | $10.83 | $174,417.15 |
DisclosureSEC source: 0001140361-23-041198 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611,813 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 01:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 59,811 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-040145 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,523,578 Underlying: Common Shares · 59,811 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 01:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 59,811 | $11.89 | $711,152.79 |
DisclosureSEC source: 0001140361-23-040145 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 14, 2023 Filed Aug 17, 2023 01:34 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 59,811 | $3.85 | $230,272.35 |
DisclosureSEC source: 0001140361-23-040145 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 687,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,629 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-038432 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,583,389 Underlying: Common Shares · 44,629 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 44,629 | $11.93 | $532,423.97 |
DisclosureSEC source: 0001140361-23-038432 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 03, 2023 Filed Aug 8, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 44,629 | $3.85 | $171,821.65 |
DisclosureSEC source: 0001140361-23-038432 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,397 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,628,018 Underlying: Common Shares · 16,397 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 16,397 | $11.86 | $194,468.42 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 16,397 | $3.85 | $63,128.45 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,397 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,644,415 Underlying: Common Shares · 61,397 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 61,397 | $11.92 | $731,852.24 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 61,397 | $3.85 | $236,378.45 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 117,372 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · derivative · entry 7 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,705,812 Underlying: Common Shares · 117,372 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 31, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 117,372 | $11.91 | $1,397,900.52 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| July 31, 2023 Filed Aug 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 117,372 | $3.85 | $451,882.20 |
DisclosureSEC source: 0001140361-23-037718 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,622 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,823,184 Underlying: Common Shares · 23,622 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 23,622 | $10.98 | $259,369.56 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 23,622 | $3.85 | $90,944.70 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 651,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 73,568 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,846,806 Underlying: Common Shares · 73,568 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 73,568 | $10.91 | $802,626.88 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 73,568 | $3.85 | $283,236.80 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,344 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · derivative · entry 7 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,920,374 Underlying: Common Shares · 28,344 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 25, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 28,344 | $10.86 | $307,815.84 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. Read SEC document |
| July 25, 2023 Filed Jul 28, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 28,344 | $3.85 | $109,124.40 |
DisclosureSEC source: 0001140361-23-036583 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,081 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · derivative · entry 10 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,948,718 Underlying: Common Shares · 33,081 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 16,297 | $10.99 | $179,104.03 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 7 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,918 F3 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. These sales was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 33,081 | $10.93 | $361,575.33 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 6 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,215 F1 · shares: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 33,081 | $3.85 | $127,361.85 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 5 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 181,998 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · derivative · entry 9 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,981,799 Underlying: Common Shares · 181,998 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 181,998 | $11.13 | $2,025,637.74 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,215 F1 · shares: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 181,998 | $3.85 | $700,692.30 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 826,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 159,387 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · derivative · entry 8 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,163,797 Underlying: Common Shares · 159,387 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| July 20, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 159,387 | $11.31 | $1,802,666.97 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,215 F1 · shares: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 20, 2023 Filed Jul 25, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 159,387 | $3.85 | $613,639.95 |
DisclosureSEC source: 0001140361-23-035930 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 803,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2023 Filed Jun 27, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 15,882 | $10.01 | $158,978.82 |
DisclosureSEC source: 0001140361-23-031547 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,215 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 09, 2023 Filed Jun 10, 2023 01:32 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 299,384 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-23-029190 · form4.xml · derivative · entry 6 Venker Eric · CIK 0001801917 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,323,184 Underlying: Common Shares · 299,384 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.